- Policy
- Recruitment of 733 COVID-19 cured patients was completed
- by Lee, Hye-Kyung Aug 3, 2020 11:06am
- 1098 patients who were cured revealed their willingness to participate in the development of COVID-19 blood plasma, of which 733 were recruited. At the regular briefing held on the 30th, Kwon Jun-wook, Deputy director of the Central Disease Control Headquarters said, “Recruitment of 733 plasma for cured patients was completed and recovery
- Policy
- The promotion for the KCDC are in progress
- by Lee, Jeong-Hwan Aug 3, 2020 11:05am
- On the 28th, the Public Administration and Security Committee held a general meeting without any member of the opposition party, and decided to amend the government organizational law, which included the introduction of multiple vice ministers by the MOHW and the promotion of the KCDC to the Disease Control and Prevention Service. As a re
- Policy
- MFDS to independently investigate data manipulation
- by Lee, Jeong-Hwan Jul 31, 2020 06:33am
- “This day in K-Bio is a hurdle we have to overcome to become the new drug developing country that tackles unmet medical needs. But we have already started working on creating fertile grounds to leverage the Korean-made pharmaceuticals in the global market by utilizing this hurdle as an opportunity to tighten administrative investigational p
- Policy
- “Primary care-based remote medicine as a supplement"
- by Lee, Jeong-Hwan Jul 30, 2020 06:20am
- To respond against novel infectious disease like COVID-19 and super-aged society, experts claim the South Korean society should prepare for an introduction to digital healthcare and remote medicine. In particular, the experts pointed out the remote medicine (non-contact medical care) would not replace the traditional medical care, but it
- Policy
- Biosimilars are growing at 52% among pharmaceutical exports
- by Lee, Hye-Kyung Jul 30, 2020 06:18am
- Pharmaceutical exports in the first half of this year were $3.8 billion, up 52.5% from the previous year's $2.5 billion. Biosimilars account for 52% of export items ($1.98 billion). he KHIDI (Director, Deok-cheol Kwon) held a press conference at 11:00 am on the 29th and announced major performance trends such as health industry exports, jo
- Policy
- NECA, the safety and effectiveness of Epidyolex & Sativex
- by Lee, Hye-Kyung Jul 30, 2020 06:17am
- The NECA announced on the 28th that it has drawn the first social consensus on the safety and effectiveness of Epidyolex and Sativex, a hemp-derived drug approved in Korea. Recently, With Byung-Joo Park, Professor of the Department of Preventive Medicine, Seoul National University, Young-Chul Kang, Professor of Department of Pediatrics, Sever
- Policy
- Nesp, cheaper than biosimilar due to voluntary price cut
- by Lee, Tak-Sun Jul 29, 2020 09:45pm
- The second-generation EPO 'Nesp' (Darbepoetin alfa/Kyowa Kirin, Korea) has become cheaper than biosimilar through voluntary cuts in insurance premiums. According to the MOHW, as of August 1st, Nesp cut its insurance upper limit by 12.5% for each dose. Accordingly, in the case of Nesp PFS 20, it was lowered from \19,898 to \17,411. Last
- Policy
- Tecentriq combo wins coverage as first-line on NSCLC
- by Lee, Hye-Kyung Jul 28, 2020 06:37am
- Roche Korea’s Tecentriq (atezolizumab) is to receive coverage on treating patients with non-small cell lung cancer (NSCLC) as a first-line treatment. South Korea’s Health Insurance Review and Assessment Service (HIRA) disclosed the revised notice on anticancer treatment with the said update, which would accept public opinion on the rev
- Policy
- Copayment of Choline alfoscerate other than dementia is 80%
- by Kim, Jung-Ju Jul 28, 2020 06:36am
- The government's commitment to the re-evaluation of the already listed Choline alfoscerate was clear, and the results of the re-evaluation of Choline alfoscerate, which had strong social demands, eventually ended up maintaining the benefits only for dementia. The government left only the task of applying the revision after making an admi
- Policy
- Multiple myeloma drug Farydak was revoked after approval
- by Lee, Jeong-Hwan Jul 28, 2020 06:33am
- Farydak (Panobinostat), which can be used for patients who have failed to administer Velcade (Bortezomib), was revoked after three years of domestic marketing approval. There are many domestically licensed multiple myeloma medications, and the track listings, such as Risk-Sharing Agreement (RSA), have had an effect on the cancellation of t
